Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023)

Grifols (GRFS) reported Income from Non-Controlling Interests of $130569.6 for Q4 2023, up 103.57% on a YoY basis from $64139.9 in Q4 2022, and up 103.57% quarter-over-quarter from $64139.9 in Q4 2022.

Grifols (GRFS) Income from Non-Controlling Interests (2010 - 2023) Analysis & Trends

Grifols has reported Income from Non-Controlling Interests for 12 years, with the latest figure at $130569.6 in Q4 2023.

  • For the quarter ending Q4 2023, Income from Non-Controlling Interests rose 103.57% year-over-year to $130569.6; the trailing twelve-month figure through Dec 2023 stood at -$18.6 million (down 11.57% YoY), and the FY2025 full-year result was $114.1 million, up 90.63% from the prior year.
  • Income from Non-Controlling Interests for Q4 2023 stood at $130569.6, up from $64139.9 in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $130569.6 in Q4 2023, with the low at -$18.9 million in Q1 2020.
  • Historically, Income from Non-Controlling Interests has averaged -$4.7 million across 4 years, with a median of $82649.9 in 2019.
  • Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests soared 115.33% — and 2020, when it sank 18826.37%.
  • Grifols' Income from Non-Controlling Interests stood at $101160.0 in 2019, then slumped by 18826.37% to -$18.9 million in 2020, then jumped by 100.34% to $64139.9 in 2022, then jumped by 103.57% to $130569.6 in 2023.
  • The last three Income from Non-Controlling Interests figures came in at $130569.6 (Q4 2023), $64139.9 (Q4 2022), and -$18.9 million (Q1 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.48 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 2.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -3.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 8.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 1.00 Mn
10 Grifols 6.05 Bn 5.09 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 130,569.61
Dec 31, 2022 64,139.89
Mar 31, 2020 -18.94 Mn
Mar 31, 2019 101,159.97
Dec 31, 2018 2.06 Mn
Jun 30, 2018 668,328.87
Mar 31, 2018 -659,722.11
Dec 31, 2017 -1.22 Mn
Jun 30, 2017 256,194.99
Mar 31, 2017 -274,874.98
Dec 31, 2016 -353,069.82
Sep 30, 2016 256,722.43
Jun 30, 2016 76,831.50
Dec 31, 2015 -1.98 Mn
Sep 30, 2015 201,323.57
Jun 30, 2015 523,836.96
Mar 31, 2015 -754,728.11
Sep 30, 2013 967,278.17
Jun 30, 2013 1.19 Mn
Mar 31, 2013 1.92 Mn